The GRB7 (Growth Factor Receptor-Bound Protein 7) antibody is a tool used to study the role of GRB7. an adaptor protein involved in signal transduction pathways regulating cell proliferation, migration, and survival. GRB7 contains an SH2 domain that enables interaction with phosphorylated tyrosine residues on activated receptor tyrosine kinases (RTKs), such as HER2/ErbB2 and EGFR, linking them to downstream signaling molecules like Ras/MAPK and PI3K/AKT pathways. Overexpression of GRB7 is frequently observed in cancers, particularly HER2-positive breast and gastric cancers, where it is often co-amplified with HER2 due to their proximity on chromosome 17q12. This association has made GRB7 a potential biomarker and therapeutic target in oncology.
GRB7 antibodies are essential for detecting GRB7 expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). They help elucidate GRB7's functional role in tumor progression, metastasis, and drug resistance. Studies suggest GRB7 promotes cancer cell invasion by interacting with focal adhesion kinase (FAK) and integrins. Additionally, GRB7 antibodies are used to explore its involvement in non-cancer processes, such as angiogenesis and insulin signaling. Research continues to focus on developing therapeutic strategies, including peptide inhibitors or small molecules, to disrupt GRB7-mediated oncogenic interactions, highlighting its clinical relevance.